Mumbai, July 21 -- Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA(R)) administered over 24 weeks for treatment of active psoriatic arthritis.

Published by HT Digital Content Services with permission from Capital Market....